Press Releases

Date Title and Summary
Toggle Summary Accuray to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SUNNYVALE, Calif. , Feb. 7, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the virtual BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference , which takes place February 14-16, 2023 .     BTIG-hosted events are intended for
Toggle Summary Accuray Reports Fiscal 2023 Second Quarter Financial Results
Delivered strong Q2 performance amidst challenging macroenvironment; Reiterate fiscal year guidance     SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2023 ended December 31, 2022 .
Toggle Summary Robert C. Kill Joins Accuray Board of Directors
SUNNYVALE, Calif. , Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023 . Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming
Toggle Summary European Radiosurgery Center Munich Invests in Second Accuray CyberKnife® System to Support the Demand for High-Precision Radiosurgery Treatments
Center believes the CyberKnife System is the #1 tool for delivery of advanced radiosurgery treatments Selected the latest generation CyberKnife S7™ System to increase the number of indications they can treat throughout the body, and the patients they can help SUNNYVALE, Calif. , Jan.
Toggle Summary Accuray to Report Second Quarter Fiscal 2023 Financial Results on February 1, 2023
SUNNYVALE, Calif., Jan. 18, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2023, ended December 31, 2022, after the market close on February 1, 2023. Management will host a conference call to review the results at 1:30
Toggle Summary Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device
Auckland Radiation Oncology Selected the Latest-Generation CyberKnife S7™ System to Deliver Precise Treatments More Quickly, so Patients Can Rapidly Return to the Activities They Enjoy SUNNYVALE, Calif. , Jan. 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that
Toggle Summary Accuray to Participate in the B. Riley Securities' 3rd Annual Oncology Conference
Company to Take Part in Fireside Chat Wednesday, January 18, 2023 at 7:00am PST / 10:00am EST SUNNYVALE, Calif. , Jan. 10, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the B. Riley Securities' 3rd Annual Oncology Conference taking place January
Toggle Summary Accuray Receives IMV Award for Best In Service in Radiation Oncology for 2022
SUNNYVALE, Calif. , Nov. 28, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its commitment to delivering better, faster cancer treatment technology and superior service is resulting in highly satisfied customers. According to the IMV ServiceTrak™ Radiation Oncology
Toggle Summary Oscar Lambret Center in France Installs Second Accuray Radixact® System, the Hospital's Fifth Accuray Radiation Therapy Delivery System
Hospital Adds Accuray ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony ® Technologies to Both Radixact Systems, Creating the Ultimate System for Personalized Cancer Care SUNNYVALE, Calif. , Nov. 16, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Oscar Lambret
Toggle Summary Accuray Reports Fiscal 2023 First Quarter Financial Results
Strong customer demand. Navigating FX and Supply Chain Challenges. Company reiterates full year guidance.  SUNNYVALE, Calif. , Nov. 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2023 ended September 30, 2022 .

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.